Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion.
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
23 Jan 2019
23 Jan 2019
Historique:
received:
22
08
2018
accepted:
16
01
2019
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
8
2
2019
Statut:
epublish
Résumé
Plasmodium vivax malaria elimination can only be achieved by the deployment of 8-aminoquinolines (primaquine and tafenoquine) in combination with ACT to kill both blood and liver-stage parasites. However, primaquine and the other 8-aminoquinolines cause dose-dependent haemolysis in subjects with G6PD deficiency, an X-linked disorder of red blood cells that is very common in populations living in tropical and subtropical areas. In order to inform safer use of 8-aminoquinolines in the Greater Mekong Subregion, a multi-centre study was carried out to assess the prevalence of G6PD deficiency and to identify the main G6PD variants in samples collected in Cambodia, Lao PDR, Myanmar, Thailand and Vietnam. Blood samples were collected in the five countries during National Malaria Surveys or during Population Surveys. During Population Surveys samples were characterized for G6PD phenotype using the Fluorescent Spot Test. Samples were then genotyped for a panel of G6PD mutations. G6PD deficiency was found to be common in the region with an overall mean prevalence of deficient or mutated hemizygous males of 14.0%, ranging from a mean 7.3% in Thailand, 8.1% in Lao PDR, 8.9% in Vietnam, 15.8% in Myanmar and 18.8% in Cambodia. Mahidol and Viangchan mutations were the most common and widespread variants found among the nine investigated. Owing to the high prevalence of G6PD deficiency in the Greater Mekong Subregion, strategies for vivax malaria elimination should include point-of-care G6PD testing (both qualitative and quantitative) to allow safe and wide treatment with 8-aminoquinolines.
Sections du résumé
BACKGROUND
BACKGROUND
Plasmodium vivax malaria elimination can only be achieved by the deployment of 8-aminoquinolines (primaquine and tafenoquine) in combination with ACT to kill both blood and liver-stage parasites. However, primaquine and the other 8-aminoquinolines cause dose-dependent haemolysis in subjects with G6PD deficiency, an X-linked disorder of red blood cells that is very common in populations living in tropical and subtropical areas. In order to inform safer use of 8-aminoquinolines in the Greater Mekong Subregion, a multi-centre study was carried out to assess the prevalence of G6PD deficiency and to identify the main G6PD variants in samples collected in Cambodia, Lao PDR, Myanmar, Thailand and Vietnam.
METHODS
METHODS
Blood samples were collected in the five countries during National Malaria Surveys or during Population Surveys. During Population Surveys samples were characterized for G6PD phenotype using the Fluorescent Spot Test. Samples were then genotyped for a panel of G6PD mutations.
RESULTS
RESULTS
G6PD deficiency was found to be common in the region with an overall mean prevalence of deficient or mutated hemizygous males of 14.0%, ranging from a mean 7.3% in Thailand, 8.1% in Lao PDR, 8.9% in Vietnam, 15.8% in Myanmar and 18.8% in Cambodia. Mahidol and Viangchan mutations were the most common and widespread variants found among the nine investigated.
CONCLUSIONS
CONCLUSIONS
Owing to the high prevalence of G6PD deficiency in the Greater Mekong Subregion, strategies for vivax malaria elimination should include point-of-care G6PD testing (both qualitative and quantitative) to allow safe and wide treatment with 8-aminoquinolines.
Identifiants
pubmed: 30674319
doi: 10.1186/s12936-019-2652-y
pii: 10.1186/s12936-019-2652-y
pmc: PMC6343352
doi:
Substances chimiques
G6PD protein, human
EC 1.1.1.49
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : France's 5% Initiative
ID : 12INI211
Références
Hum Mutat. 2002 Feb;19(2):185
pubmed: 11793482
Nature. 1961 Apr 22;190:372-3
pubmed: 13764598
Arch Intern Med. 1962 Feb;109:209-34
pubmed: 13919680
J Hum Genet. 2008;53(1):48-54
pubmed: 18046504
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Biotechniques. 1991 Apr;10(4):506-13
pubmed: 1867860
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
N Engl J Med. 2009 Jul 30;361(5):540-1
pubmed: 19641219
PLoS One. 2011;6(12):e28357
pubmed: 22164279
Malar J. 2011 Dec 15;10:368
pubmed: 22171972
Sci Rep. 2012;2:299
pubmed: 22393475
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
Malar J. 2013 Nov 15;12:418
pubmed: 24228846
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Am J Trop Med Hyg. 2014 Jul;91(1):77-80
pubmed: 24778197
Am J Trop Med Hyg. 2015 Jan;92(1):22-7
pubmed: 25385861
PLoS One. 2014 Dec 23;9(12):e116063
pubmed: 25536053
PLoS One. 2014 Dec 26;9(12):e116143
pubmed: 25541721
BMC Med. 2015 Dec 14;13:296
pubmed: 26652887
PLoS One. 2016 Mar 24;11(3):e0151898
pubmed: 27010542
PLoS Negl Trop Dis. 2016 May 04;10(5):e0004582
pubmed: 27144482
Malar J. 2016 Jun 14;15:319
pubmed: 27301553
Malar J. 2016 Aug 26;15(1):436
pubmed: 27566274
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Trends Parasitol. 2017 May;33(5):353-363
pubmed: 28187990
Am J Trop Med Hyg. 2017 Sep;97(3):702-711
pubmed: 28749773
Malar J. 2017 Jul 27;16(1):301
pubmed: 28750669
Wellcome Open Res. 2017 Nov 2;2:72
pubmed: 29181452
Wellcome Open Res. 2017 Dec 22;2:98
pubmed: 29384151
Lancet Infect Dis. 2018 May;18(5):565-572
pubmed: 29398388
Lancet Infect Dis. 2018 Mar;18(3):337-345
pubmed: 29398391
Malar J. 2018 Mar 2;17(1):101
pubmed: 29499733
PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440
pubmed: 29677199
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425
PLoS One. 2018 May 8;13(5):e0196716
pubmed: 29738562
Blood. 1968 Nov;32(5):816-8
pubmed: 4386875
Am J Hematol. 1996 Jan;51(1):19-25
pubmed: 8571933
Br J Haematol. 1977 Feb;35(2):331-40
pubmed: 857853